Corneal Endothelial Cell Differentiation from Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating ocular degenerative diseases such as age-related macular degeneration, retinitis pigmentosa, and corneal endothelial dystrophy are limited due to the challenges of expanding and differentiating adult progenitor cells, ethical concerns with fetal retinal cells, and the inefficiency of human pluripotent stem cells in direct transplantation, particularly in generating specialized eye cells like retinal pigmented epithelium, photoreceptors, and corneal endothelial cells.
Innovation Solution
A small molecule-driven differentiation approach is used to restrict the pluripotent state of human stem cells to a primitive neuroepithelial eye field state, allowing for the directed differentiation into retinal and neural crest lineages, including retinal pigmented epithelium, photoreceptors, retinal ganglion cells, and corneal endothelial cells, under chemically defined conditions, using specific signaling pathways and inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If human pluripotent stem cells are used for direct transplantation, then the renewable donor source is provided, but the teratoma formation and low repopulation efficiency occur
Solution Approach 1:
The patent segments the differentiation process into distinct stages: first generating eye field stem cells from PSCs, then further differentiating them into specific retinal cell types (RPE, photoreceptors, RGCs). This staged approach prevents teratoma formation by ensuring complete differentiation while maintaining the renewable nature of PSC-derived cells
Solution Approach 2:
The patent performs preliminary differentiation of PSCs into eye field stem cells before transplantation, and further preliminary differentiation into specific retinal cell types before clinical use. This preliminary action ensures cells are fully differentiated and committed to specific lineages, eliminating teratoma risk while preserving the renewable donor source advantage
2Adaptability or versatility
If adult progenitor cells are used for grafting, then the ethical concerns are avoided, but the expansion capacity and differentiation potential are limited
Solution Approach 1:
The patent changes the biological parameters of the cell source by using PSCs (which have unlimited expansion capacity) instead of adult progenitor cells. By controlling differentiation parameters through specific culture conditions and small molecules, the patent directs PSCs to become eye field stem cells and then specific retinal cell types, achieving both ethical acceptability and high productivity
3Reliability
If fetal retinal progenitors are used for transplantation, then the differentiation potential is improved, but the difficulty of obtaining sufficient cells and ethical concerns arise
Solution Approach 1:
The patent performs preliminary differentiation of PSCs into eye field stem cells under controlled conditions, then further differentiates them into specific retinal cell types in sufficient quantities. This preliminary action sequence allows obtaining unlimited numbers of differentiated cells with proven differentiation potential, avoiding the scarcity and ethical issues of fetal progenitors
Solution Approach 2:
The patent uses PSCs that can self-renew indefinitely in culture, eliminating the need to obtain cells from fetal sources. The PSCs serve their own purpose of generating unlimited supplies of differentiated retinal cells through controlled differentiation protocols
Data Source
AI summary
Compositions and methods for producing major ocular cell types, including retinal ganglion cells, photoreceptors, retinal pigmented epithelium and corneal endothelial cells, from human pluripotent stem cells under defined culture conditions are provided.